elisa 300, elisa 500, elisa 600, elisa 800, elisa 800VIT | ICU EQUIPMETNS Neonate, Paediatric & Adult Ventilation 🔹 Affordable & High-Quality Equipment 🔹 Customized Solutions for Hospitals & Clinics 🔹 Trusted by Healthcare Professionals ✅Turn-Key Solutions for Hospital Setup and Healthcare Services Contact Us : 📞 +91 9916515255 📧 contact@medasus.com 🌐 https://medasus.com/ #icu #ICUequipment #elisa300 #elisa500 #elisa600 #ELISA800 #elisa800vit #medasus #hospital #HospitalSupplies #ventilation #dseide #pediatrics #pediatricequipments #neonatalcare

Are you struggling to land that dream healthcare job? Don’t worry, Vaidyog is here to help! If you are facing difficulties in landing a healthcare job, look no further than Vaidyog. Our platform is designed to facilitate your job search and help you find the perfect fit for your skills. Start your search with Vaidyog today! Get In Touch : 📧 info@vaidyog.com 🌐 https://vaidyog.com/ #vaidyog #healthcare #healthcarejobs #HealthcareEmpowerment #doctors #FacebookPage #facebookreelsviral #indian #nursing #nursingstudent #medical #medicaljobs #hospital #clinics #jobsearch #JobsInIndia #careers #jobs #jobopportunity

Join Us for the Emergencies in Geriatric Critical Care Workshop at GSICON 2024 on 13th December 2024 at IMA House, Kochi This workshop, conducted by the Indian Society Of Critical Care Medicine, Cochin City Branch, is an incredible opportunity to deepen your understanding of critical care for elderly patients. Topics Covered: * Fluid Resuscitation in Geriatric Critically Ill Patients * Electrolyte Disturbances in Geriatric ICU Patients * Delirium in Geriatric ICU Patients * End of Life Care in Geriatric Critical Care Stations * HFNC * Noninvasive ventilation: * Ventilation Basics * Ventilation COPD & ARDS Don't miss this chance to enhance your skills and knowledge in geriatric critical care. Register now and be a part of this essential learning experience. Register Now: https://www.gsicon2024.in/ hashtag#GeriatricCare hashtag#CriticalCare hashtag#HealthyAging hashtag#GSICON2024 hashtag#Workshop

🚀 The Infertility Treatment Market is Booming: Here’s Why Now is the Time to Invest! 🚀 The global infertility treatment market is in the midst of a powerful transformation, creating unique opportunities for businesses ready to innovate and grow. With the market projected to double from $1.9 billion in 2024 to $3.8 billion by 2034, the future is bright for this sector 🌟. Why the Growth? Tech Advancements 🌐: Cutting-edge technologies—like AI-driven embryo selection, time-lapse imaging, and enhanced fertility diagnostics—are making treatments more successful and accessible. This innovation is drawing more people than ever to fertility clinics. Shifting Societal Attitudes 🌱: What was once stigmatized is now being openly discussed and embraced. High-profile voices and shifting norms are making fertility treatments mainstream, empowering couples to seek help early and confidently. Demographic Changes 🌎: Career priorities, lifestyle changes, and later family planning are impacting fertility rates, particularly in developed countries. This trend is pushing demand for fertility solutions and driving the market. Government & Institutional Support 💼: Countries like Germany are investing in reproductive health research, expanding the possibilities of fertility treatments and helping make them more affordable. Regional Highlights 📊 North America & Europe: The U.S. and Germany are leading with steady growth, while rising healthcare innovation drives the market forward. Asia-Pacific: India and China are showing phenomenal growth, with India expected to see an 8.3% CAGR thanks to a young, health-conscious demographic. The Bottom Line This market is fertile ground for businesses ready to embrace change, invest in tech, and support a growing number of individuals on their fertility journey. With society opening up, technology advancing, and demand surging, the question isn’t if you should join the movement—it’s how soon! 💡 #Healthcare #Innovation #InfertilityTreatment #BusinessGrowth #FutureOfHealthcare

Join us at GSICON 2024 for an insightful session on " Medical Assessment in the Elderly: Is that different from the Young?" led by the esteemed Prof . Dr. R. Krishnan MBBS, MD, former HOD of Medicine at CMC & MES and Senior Consultant at Baby Memorial Hospital, Calicut. Dates: 13th, 14th, & 15th December Venue: IMA House, Kochi Register now to secure your spot! Click here to register: https://www.gsicon2024.in/

Join us at GSICON 2024 for an insightful session on " Medical Assessment in the Elderly: Is that different from the Young?" led by the esteemed Prof . Dr. R. Krishnan MBBS, MD, former HOD of Medicine at CMC & MES and Senior Consultant at Baby Memorial Hospital, Calicut. Dates: 13th, 14th, & 15th December Venue: IMA House, Kochi Register now to secure your spot! Click here to register: https://www.gsicon2024.in/

https://www.amritahospitals.org/kochi/news/amrita-hospital-kochi-launches-swallo-app-people-swallowing-difficulties

Exciting news in the world of pediatric health! Researchers have made significant progress in developing a vaccine against Respiratory Syncytial Virus (RSV), a common virus that causes severe respiratory illness in young children. Pfizer's vaccine, called ABRYSVO, has shown promising results in clinical trials, particularly among immunocompromised adults and older adults . In fact, the FDA has already approved ABRYSVO for preventing lower respiratory tract disease caused by RSV in individuals 60 years of age or older, as well as for pregnant individuals to help protect infants from birth up to six months of age . Key Benefits of ABRYSVO: *Prevents lower respiratory tract disease caused by RSV in individuals 60 years of age or older. *Helps protect infants from birth up to six months of age when administered to pregnant individuals. *Shows strong neutralizing responses against both RSV-A and RSV-B subtypes. Ongoing Research: Pfizer has initiated a clinical trial evaluating ABRYSVO in children ages two to less than 18 years who are at higher risk for RSV disease . This is a significant step forward in protecting younger populations from the devastating effects of RSV. These breakthroughs offer new hope for vulnerable populations, and we can expect even more advancements in the fight against RSV in the coming years!

"Diagnostics Firm Redcliffe Labs Raises $42M in Series C Round" Redcliffe Labs, an omnichannel diagnostics service provider, has secured $42 million in Series C funding, led by Denmark's Investment Fund for Developing Countries (IFU) with a $20 million investment, followed by existing investor LeapFrog Investments with $15 million. The remaining capital came from existing shareholders HealthQuad and Spark Growth Ventures.This funding will fuel Redcliffe's expansion plans, focusing on deepening its presence in Tier-II and Tier-III cities across India. The company plans to open more labs and collection centers, expand its home collection network, and pursue strategic partnerships and acquisitions . Redcliffe's goal is to democratize access to high-quality, affordable, and accurate diagnostics for every Indian, particularly in underserved populations. The company currently operates over 80 labs, processes tests from 2,000 collection centers, and has a network of 1,000 phlebotomists across 220 cities in India . SOURCE- Business Standard #RedcliffeLabs, #SeriesCFunding, #HealthcareFunding, #DiagnosticsIndustry #IndianHealthcare , #StartupFunding , #HealthTech ,#MedicalDiagnostics #IndiaExpansion #HealthcareInnovation #FundingNews #StartupNews #IndianStartupEcosystem #HealthcareStartup

Fortis Bengaluru Hits 1,000 Robot-Aided Urological Procedures Milestone: Bengaluru, has reached an impressive milestone by performing over 1000 Robot-aided surgeries using the Da Vinci Xi Robotic Surgical System at Bannerghatta Road highlighting the hospital’s expertise and commitment to advanced surgical techniques. This accomplishment not only underscores the hospital’s capabilities but also its role in leading the adoption of cutting-edge technology in urology. In addition, the introduction of the Da Vinci X system at Fortis Cunningham Road signifies the hospital’s ongoing investment in expanding access to state-of-the-art surgical options. Fortis Hospital, Bengaluru is at the forefront of integrating robotic technology into their surgical practices, which has led to improved patient outcomes, shorter recovery times, and increased precision in complex procedures. The Urology Team led by Dr. Mohan Keshavamurthy, has successfully performed more than 1,000 robotic surgeries over the past 79 months, since the installation of the Da Vinci surgical system at Fortis Bannerghatta Road in 2018. These surgeries span a broad range of complex procedures across Uro-Oncology, Uro-Gynaecology, Reconstructive Urology, and Kidney Transplantation. The surgeries conducted via Da Vinci Xi Robot include 92 Robotic Kidney Transplants, 398 Nerve-Sparing Robotic Radical Prostatectomies, 282 Robotic Complex Partial Nephrectomies and 54 Pediatric Robotic Procedures, amongst others. One such case is that of Patient Amar (name changed), a 50-year-old man who underwent multiple procedures in his hometown Kolkata, for a stone in the Ureter. During the surgical procedure, there were intra-operative complications that led to a traumatic injury to the ureter. A surgical procedure to examine the abdominal cavity was performed, however the ureter could not be repaired. As a result of the injured ureter, a tube was inserted to drain urine from the kidney (Nephrostomy). These complications led to recurrent urinary tract infections in the patient, requiring multiple ICU admissions. The patient was eventually airlifted from Kolkata to Fortis Bannerghatta Road, Bengaluru, where doctors successfully performed robot-assisted laparoscopic surgery to repair the ureteric injury. Source- Business News #technology #Robotics